PolyCol’s ability to rapidly repair the damaged collagen present in dry eye disease, coupled with the concurrent recovery of the corneal epithelium and reduction of inflammation, make this the company’s initial focus through the drug candidate ST-100. Future development opportunities for this ocular surface drop formulation include Allergic Conjunctivitis, Corneal Trauma, and Corneal Ulcers. The development of ST-100 is supported by compelling animal testing results, with complete healing of damaged corneal tissues in 24 hours or less. Other variants of the PolyCol platform have demonstrated promise in two major diseases with significant unmet need: Glaucoma and Dry Age-Related Macular Degeneration (Dry AMD). Stuart has completed a series of research programs that demonstrate the benefits of repair and restoration of triple helix collagen in the affected tissues commonly associated with both of these disease indications. These results suggest a completely novel approach to treating these chronic indications.
For dry eye disease, Stuart Therapeutics is taking advantage of PolyCol’s rapid tissue repair capability to directly address the causal tissue damage that results in inflammation for this indication. The ST-100 drug candidate is expected to provide quick relief for ocular surface damage caused by dry eye disease, healing damaged corneal and conjunctival tissues, with patient relief expected in 24 to 48 hours, compared with several weeks for competing alternatives.
For glaucoma, a PolyCol variant acts to heal biophysical damage to collagen in the lamina cribrosa and retrolaminar region, which are part of the supporting tissues for optic nerve axons as they exit the eye. Normal collagen cell signaling function is restored. This repair acts to protect the nerve axons, preventing loss of visual function.
Stuart Therapeutics is a clinical stage company, with several drugs in development. Click here to learn more about the company’s trials, study sites, and opportunities for participation.